{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:53:00Z","timestamp":1793116380641,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003945","name":"Link\u00f6ping University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Studies on the association between lipid levels and lipid-lowering treatment and the risk of dementia and\/or cognitive decline (CD) have shown conflicting results and are few in individuals with type 2 diabetes (T2D). The aim was to evaluate the relationship of baseline LDL cholesterol levels and statin treatment with the development of dementia\/CD in patients with T2D from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation trial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Dementia was diagnosed using the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV), and CD was defined as at least a 3-point decrement in the Mini Mental State Examination score. Exposures were baseline LDL cholesterol levels, statin treatment at baseline, and statin treatment initiation during the first 18\u00a0months of follow-up. Multinomial logistic regression was used to estimate the odds ratio (OR) and 95% CI for the composite of dementia\/CD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 11,140 participants, 1827 (16.4%) developed dementia\/CD over the 5-year follow up. The OR (95% CI) of dementia\/CD were 1.06 (1.00\u20131.14) per standard deviation higher in baseline LDL cholesterol and 0.90 (0.79\u20131.03) for participants with vs without statin treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We observed an association between LDL levels, but not statin treatment, and incident dementia\/CD. Although causality cannot be determined by our study, the results are in line with multiple randomised controlled trials. However, to understand the long-term effects of lipid levels and statin treatment on dementia\/CD, studies of longer follow-up are still needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12933-025-02894-3","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T11:52:53Z","timestamp":1755517973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lipoprotein levels and statin treatment related to dementia and cognitive decline in individuals with type 2 diabetes: an observational analysis from the ADVANCE study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6038-5131","authenticated-orcid":false,"given":"Peder","family":"af Geijerstam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9931-0580","authenticated-orcid":false,"given":"John","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-207X","authenticated-orcid":false,"given":"Miriam","family":"Pikkemaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0148-3617","authenticated-orcid":false,"given":"Ruth","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3071-1837","authenticated-orcid":false,"given":"Michel","family":"Marre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0942-3176","authenticated-orcid":false,"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9800-5296","authenticated-orcid":false,"given":"Mark","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2444-2869","authenticated-orcid":false,"given":"Katie","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"2894_CR1","doi-asserted-by":"crossref","unstructured":"Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, Pena JM, Selim MH, Woo D, American Heart Association Council on Arteriosclerosis T, Vascular B et al. Aggressive LDL-C lowering and the brain: impact on risk for dementia and hemorrhagic stroke: a scientific statement from the american heart association. Arterioscler Thromb Vasc Biol 2023, 43(10):e404\u201342","DOI":"10.1161\/ATV.0000000000000164"},{"issue":"10","key":"2894_CR2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1017\/S1355617714000885","volume":"20","author":"GE Crichton","year":"2014","unstructured":"Crichton GE, Elias MF, Davey A, Sullivan KJ, Robbins MA. Higher HDL cholesterol is associated with better cognitive function: the Maine-Syracuse study. J Int Neuropsychol Soc. 2014;20(10):961\u201370.","journal-title":"J Int Neuropsychol Soc"},{"issue":"16","key":"2894_CR3","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","volume":"140","author":"NA Marston","year":"2019","unstructured":"Marston NA, Giugliano RP, Im K, Silverman MG, O\u2019Donoghue ML, Wiviott SD, Ference BA, Sabatine MS. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019;140(16):1308\u201317.","journal-title":"Circulation"},{"issue":"1","key":"2894_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10557-020-07045-2","volume":"35","author":"H Ying","year":"2021","unstructured":"Ying H, Wang J, Shen Z, Wang M, Zhou B. Impact of lowering low-density lipoprotein cholesterol with contemporary lipid-lowering medicines on cognitive function: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2021;35(1):153\u201366.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"16","key":"2894_CR5","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1016\/j.scib.2021.02.018","volume":"66","author":"R Hua","year":"2021","unstructured":"Hua R, Ma Y, Li C, Zhong B, Xie W. Low levels of low-density lipoprotein cholesterol and cognitive decline. Sci Bull Beijing. 2021;66(16):1684\u201390.","journal-title":"Sci Bull Beijing"},{"issue":"18","key":"2894_CR6","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/j.jacc.2020.03.040","volume":"75","author":"JG Robinson","year":"2020","unstructured":"Robinson JG. Low LDL-C levels: likely no short-term cognitive harm. J Am Coll Cardiol. 2020;75(18):2294\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2894_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000519452","volume":"50","author":"R Peters","year":"2021","unstructured":"Peters R, Xu Y, Antikainen R, Beckett N, Gussekloo J, Jagger C, Jukema JW, Keinanen-Kiukaanniemi S, Ryden L, Skoog I, et al. Evaluation of high cholesterol and risk of dementia and cognitive decline in older adults using individual patient meta-analysis. Dement Geriatr Cogn Disord. 2021;50(4):318\u201325.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"2894_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3233\/JAD-160826","volume":"56","author":"KJ Anstey","year":"2017","unstructured":"Anstey KJ, Ashby-Mitchell K, Peters R. Updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and meta-analysis. J Alzheimers Dis. 2017;56(1):215\u201328.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2894_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12916-021-01980-z","volume":"19","author":"J Gong","year":"2021","unstructured":"Gong J, Harris K, Peters SAE, Woodward M. Sex differences in the association between major cardiovascular risk factors in midlife and dementia: a cohort study using data from the UK Biobank. BMC Med. 2021;19(1):110.","journal-title":"BMC Med"},{"issue":"1","key":"2894_CR10","doi-asserted-by":"publisher","first-page":"19383","DOI":"10.1038\/s41598-022-24153-1","volume":"12","author":"YB Lee","year":"2022","unstructured":"Lee YB, Kim MY, Han K, Kim B, Park J, Kim G, Hur KY, Kim JH, Jin SM. Association between cholesterol levels and dementia risk according to the presence of diabetes and statin use: a nationwide cohort study. Sci Rep. 2022;12(1):19383.","journal-title":"Sci Rep"},{"issue":"15","key":"2894_CR11","doi-asserted-by":"crossref","first-page":"e1630","DOI":"10.1212\/WNL.0000000000200954","volume":"99","author":"M den Brok","year":"2022","unstructured":"den Brok M, Eggink E, Hoevenaar-Blom MP, van Gool WA, Moll van Charante EP, Richard E, van Dalen JW. Low values for blood pressure, BMI, and non-HDL cholesterol and the risk of late-life dementia. Neurology. 2022;99(15):e1630\u20139.","journal-title":"Neurology"},{"issue":"12","key":"2894_CR12","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1111\/jgs.15581","volume":"66","author":"ZA Marcum","year":"2018","unstructured":"Marcum ZA, Walker R, Bobb JF, Sin MK, Gray SL, Bowen JD, McCormick W, McCurry SM, Crane PK, Larson EB. Serum cholesterol and incident Alzheimer\u2019s disease: findings from the adult changes in thought study. J Am Geriatr Soc. 2018;66(12):2344\u201352.","journal-title":"J Am Geriatr Soc"},{"issue":"5\u20136","key":"2894_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11357-016-9950-x","volume":"38","author":"J Tynkkynen","year":"2016","unstructured":"Tynkkynen J, Hernesniemi JA, Laatikainen T, Havulinna AS, Sundvall J, Leiviska J, Salo P, Salomaa V. Apolipoproteins and HDL cholesterol do not associate with the risk of future dementia and Alzheimer\u2019s disease: the national Finnish population study (FINRISK). Age (Dordr). 2016;38(5\u20136):465\u201373.","journal-title":"Age (Dordr)"},{"issue":"1","key":"2894_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41398-018-0336-y","volume":"9","author":"T Svensson","year":"2019","unstructured":"Svensson T, Sawada N, Mimura M, Nozaki S, Shikimoto R, Tsugane S. The association between midlife serum high-density lipoprotein and mild cognitive impairment and dementia after 19 years of follow-up. Transl Psychiatry. 2019;9(1):26.","journal-title":"Transl Psychiatry"},{"issue":"5","key":"2894_CR15","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/cvr\/cvab164","volume":"118","author":"EW Kjeldsen","year":"2022","unstructured":"Kjeldsen EW, Thomassen JQ, Juul Rasmussen I, Nordestgaard BG, Tybjaerg-Hansen A, Frikke-Schmidt R. Plasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic studies. Cardiovasc Res. 2022;118(5):1330\u201343.","journal-title":"Cardiovasc Res"},{"key":"2894_CR16","doi-asserted-by":"crossref","unstructured":"Ferguson EL, Zimmerman SC, Jiang C, Choi M, Swinnerton K, Choudhary V, Meyers TJ, Hoffmann TJ, Gilsanz P, Oni-Orisan A et al. Low- and high-density lipoprotein cholesterol and dementia risk over 17 years of follow-up among members of a large health care plan. Neurology 2023.","DOI":"10.1212\/WNL.0000000000207876"},{"issue":"9","key":"2894_CR17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/archinte.163.9.1053","volume":"163","author":"ZS Tan","year":"2003","unstructured":"Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, D\u2019Agostino RB, Wolf PA. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med. 2003;163(9):1053\u20137.","journal-title":"Arch Intern Med"},{"issue":"1","key":"2894_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00125-016-4118-x","volume":"60","author":"AM Murray","year":"2017","unstructured":"Murray AM, Hsu FC, Williamson JD, Bryan RN, Gerstein HC, Sullivan MD, Miller ME, Leng I, Lovato LL, Launer LJ, et al. Accordion mind: results of the observational extension of the ACCORD MIND randomised trial. Diabetologia. 2017;60(1):69\u201380.","journal-title":"Diabetologia"},{"issue":"6","key":"2894_CR19","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","volume":"37","author":"MJ Lipinski","year":"2016","unstructured":"Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, Baker NC, Torguson R, Brewer HB Jr, Waksman R. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J. 2016;37(6):536\u201345.","journal-title":"Eur Heart J"},{"issue":"3","key":"2894_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamainternmed.2013.13656","volume":"174","author":"JD Williamson","year":"2014","unstructured":"Williamson JD, Launer LJ, Bryan RN, Coker LH, Lazar RM, Gerstein HC, Murray AM, Sullivan MD, Horowitz KR, Ding J, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med. 2014;174(3):324\u201333.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"2894_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.atherosclerosis.2013.07.009","volume":"230","author":"G Corrao","year":"2013","unstructured":"Corrao G, Ibrahim B, Nicotra F, Zambon A, Merlino L, Pasini TS, Catapano AL, Mancia G. Long-term use of statins reduces the risk of hospitalization for dementia. Atherosclerosis. 2013;230(2):171\u20136.","journal-title":"Atherosclerosis"},{"key":"2894_CR22","doi-asserted-by":"publisher","first-page":"469580211019201","DOI":"10.1177\/00469580211019201","volume":"58","author":"CY Chang","year":"2021","unstructured":"Chang CY, Lin FJ, Hong JL, Wu CH. Adherence to statins use and risk of dementia among patients with diabetes and comorbid hyperlipidemia. Inquiry. 2021;58:469580211019201.","journal-title":"Inquiry"},{"issue":"1","key":"2894_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3233\/JAD-142571","volume":"47","author":"AD Heymann","year":"2015","unstructured":"Heymann AD, Ravona-Springer R, Moshier EL, Godbold J, Beeri MS. Statin use is associated with better cognitive function in elderly with type 2 diabetes. J Alzheimers Dis. 2015;47(1):55\u20139.","journal-title":"J Alzheimers Dis"},{"issue":"9590","key":"2894_CR24","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"A Patel","year":"2007","unstructured":"Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829\u201340.","journal-title":"Lancet"},{"issue":"24","key":"2894_CR25","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560\u201372.","journal-title":"N Engl J Med"},{"issue":"8","key":"2894_CR26","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1111\/dom.14391","volume":"23","author":"J Gong","year":"2021","unstructured":"Gong J, Harris K, Hackett M, Peters SAE, Brodaty H, Cooper M, Hamet P, Harrap S, Mancia G, MacMahon S, et al. Sex differences in risk factors for cognitive decline and dementia, including death as a competing risk, in individuals with diabetes: results from the ADVANCE trial. Diabetes Obes Metab. 2021;23(8):1775\u201385.","journal-title":"Diabetes Obes Metab"},{"key":"2894_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15935","author":"M Pikkemaat","year":"2024","unstructured":"Pikkemaat M, Woodward M, af Geijerstam P, Harrap S, Hamet P, Mancia G, Marre M, Poulter N, Chalmers J, Harris K. Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the ADVANCE study. Diabetes Obes Metab. 2024. https:\/\/doi.org\/10.1111\/dom.15935.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2894_CR28","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.2337\/dc11-0755","volume":"34","author":"M Woodward","year":"2011","unstructured":"Woodward M, Patel A, Zoungas S, Liu L, Pan C, Poulter N, Januszewicz A, Tandon N, Joshi P, Heller S, et al. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial. Diabetes Care. 2011;34(12):2491\u20135.","journal-title":"Diabetes Care"},{"issue":"5","key":"2894_CR29","doi-asserted-by":"publisher","first-page":"484","DOI":"10.2183\/pjab.86.484","volume":"86","author":"A Endo","year":"2010","unstructured":"Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(5):484\u201393.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"2894_CR30","unstructured":"Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations\u2014Product Details for ANDA 075300 https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/results_product.cfm?Appl_Type=A&Appl_No=075300#25394"},{"issue":"1","key":"2894_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12395","volume":"15","author":"J Wee","year":"2023","unstructured":"Wee J, Sukudom S, Bhat S, Marklund M, Peiris NJ, Hoyos CM, Patel S, Naismith SL, Dwivedi G, Misra A. The relationship between midlife dyslipidemia and lifetime incidence of dementia: a systematic review and meta-analysis of cohort studies. Alzheimers Dement (Amst). 2023;15(1): e12395.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"21","key":"2894_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030780","volume":"12","author":"A Saeed","year":"2023","unstructured":"Saeed A, Lopez O, Cohen A, Reis SE. Cardiovascular disease and Alzheimer\u2019s disease: the heart-brain axis. J Am Heart Assoc. 2023;12(21): e030780.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"2894_CR33","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jdiacomp.2016.12.009","volume":"31","author":"DG Bruce","year":"2017","unstructured":"Bruce DG, Davis WA, Davis TME. Low serum HDL-cholesterol concentrations in mid-life predict late-life cognitive impairment in type 2 diabetes: the Fremantle diabetes study. J Diabetes Complications. 2017;31(6):945\u20137.","journal-title":"J Diabetes Complications"},{"issue":"8","key":"2894_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.005562","volume":"12","author":"MG Nanna","year":"2019","unstructured":"Nanna MG, Wang TY, Xiang Q, Goldberg AC, Robinson JG, Roger VL, Virani SS, Wilson PWF, Louie MJ, Koren A, et al. Sex differences in the use of statins in community practice. Circ Cardiovasc Qual Outcomes. 2019;12(8): e005562.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9976","key":"2894_CR35","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","volume":"385","author":"C Cholesterol Treatment Trialists","year":"2015","unstructured":"Cholesterol Treatment Trialists C, Fulcher J, O\u2019Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397\u2013405.","journal-title":"Lancet"},{"issue":"3","key":"2894_CR36","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1016\/S2214-109X(21)00551-9","volume":"10","author":"ME Marcus","year":"2022","unstructured":"Marcus ME, Manne-Goehler J, Theilmann M, Farzadfar F, Moghaddam SS, Keykhaei M, Hajebi A, Tschida S, Lemp JM, Aryal KK, et al. Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. Lancet Glob Health. 2022;10(3):e369\u201379.","journal-title":"Lancet Glob Health"},{"issue":"5","key":"2894_CR37","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/eurjpc\/zwab208","volume":"29","author":"E Olmastroni","year":"2022","unstructured":"Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M, Zambon A, Catapano AL, Casula M. Statin use and risk of dementia or Alzheimer\u2019s disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022;29(5):804\u201314.","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"2894_CR38","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1097\/HJH.0000000000002862","volume":"39","author":"N Wang","year":"2021","unstructured":"Wang N, Harris K, Chalmers J, Harrap S, Mancia G, Marre M, Poulter N, Tzourio C, Williams B, Zoungas S, et al. Combination blood pressure lowering in the presence or absence of background statin and aspirin therapy: a combined analysis of PROGRESS and ADVANCE trials. J Hypertens. 2021;39(8):1689\u201396.","journal-title":"J Hypertens"},{"issue":"5","key":"2894_CR39","doi-asserted-by":"publisher","first-page":"386","DOI":"10.21037\/atm-20-3962","volume":"9","author":"MM Liu","year":"2021","unstructured":"Liu MM, Peng J, Cao YX, Guo YL, Wu NQ, Zhu CG, Gao Y, Li JJ. The difference between fasting and non-fasting lipid measurements is not related to statin treatment. Ann Transl Med. 2021;9(5):386.","journal-title":"Ann Transl Med"},{"issue":"4","key":"2894_CR40","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/FJC.0b013e3181d26469","volume":"55","author":"J Chalmers","year":"2010","unstructured":"Chalmers J, Arima H. Importance of blood pressure lowering in type 2 diabetes: focus on ADVANCE. J Cardiovasc Pharmacol. 2010;55(4):340\u20137.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"2894_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/01.JGP.0000310778.20870.ae","volume":"16","author":"KJ Anstey","year":"2008","unstructured":"Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry. 2008;16(5):343\u201354.","journal-title":"Am J Geriatr Psychiatry"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02894-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02894-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02894-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:49:21Z","timestamp":1757468961000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02894-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2894"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02894-3","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"340"}}